A Study on Ivonescimab Plus Chemotherapy as Neoadjuvant Therapy for Borderline Resectable Pancreatic Cancer
A Prospective, Single-arm, Phase II Clinical Study on the Efficacy and Safety of Ivonescimab Combined With Gemcitabine and Nab-paclitaxel (AG) Regimen as Neoadjuvant Treatment for Borderline Resectable Pancreatic Cancer
Sponsor: Tianjin Medical University Cancer Institute and Hospital
No open prediction endpoints
Endpoints are classified and published by ProgramSignal analysts.
Request endpoint coverageKey Facts
Primary Endpoints (CT.gov)
R0 and R1 resection rates
Time frame: up to 1 year
Secondary Endpoints
Adverse Events（AEs）
Major Pathological Response(MPR)
Event-Free Survival (EFS)
Eligibility Criteria
Inclusion Criteria: 1. Age ≥ 18 years and ≤ 75 years. 2. Histologically or cytologically confirmed pancreatic cancer. 3. Borderline resectable disease. 4. At least one measurable lesion (according to RECIST v1.1); and tumor diameter ≤ 6 cm, distance from the gastrointestinal mucosa ≥ 0.5 cm with no obvious signs of tumor invasion, and no obvious lymph node metastasis. 5. No prior anti-tumor treatment for pancreatic cancer. 6. ECOG performance status of 0-1. 7. Life expectancy of ≥3 months. 8. Hematologic function: Absolute neutrophil count (ANC) ≥1.5×10⁹/L, platelets (PLT) ≥100×10⁹/L, hemoglobin (Hb) ≥90 g/L, white blood cells (WBC) ≥3.0×10⁹/L. 9. Liver function: Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤2.5×ULN; total bilirubin ≤1.5×ULN. 10. Renal function: Serum creatinine (Cr) ≤1.5×ULN or creatinine clearance ≥60 ml/min (calculated by Cockroft-Gault formula). 11. Subjects with reproductive potential must use at least one medically accepted contraceptive m…
Read full criteria on CT.gov →✦ Analyst Commentary
Expert commentary on why this trial matters and what to watch for.
Request coverage →